Hepatitis B Surface Antibody
| Order Code: | HBSAB |
| Epic Lab Code: | LAB619 |
| Order Form: | A-1a General Lab or Epic Req |
Chemistry
6240 RCP
356-3527
6240 RCP
356-3527
Specimen:
Plasma
Collection Medium:
 |
| Plasma Separator Tube |
Alternate
Collection Media:
Call laboratory for additional acceptable specimen collection containers.
Minimum:
3 mL whole blood from light green top tube or TWO microtaines for
pediatric patients
Testing Schedule:
24 hrs/day, 7 days a week, including holidays.
Analytic Time:
1 hour (upon receipt in laboratory)
Reference Range:
Non-reactive; positive with vaccine administration. Non-reactive
samples have anti-HBs level less than 8.5 mIU/mL. Reactive samples
have anti-HBs level greater than or equal to 11.5 mIU/mL. The result
is indeterminate if the sample tests twice with anti-HBs results
greater than or equal to 8.5 mIU/mL but less than 11.5 mIU/mL.
Comments:
Part of initial diagnostic hepatitis profile or to verify immunity
status in patients who have received the hepatitis B vaccine. Results
include reactivity (REACTIVE or NON-REAC), immune status (IMMUNE or NON
IMM OR INDETERM) and quantitative concentration. Anti-HBs can be formed
following a hepatitis B infection or after hepatitis B
vaccination.
New analytical immunoassay instituted April 5, 2010.
New analytical immunoassay instituted April 5, 2010.
Test
Limitations:
Assay is unaffected by icterus, hemolysis (Hb < 1600 mg/dL), and
lipemia (triglycerides < 1500 mg/dL). In patients receiving high biotin
doses
(> 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No false negative findings due to the high-dose hook effect are observed up to an anti-HBs concentration of 115,000 mIU/mL. In rare cases, interference due to extremely high titers of antibodies to analyte- specific antibodies, streptavidin, or ruthenium can occur.
For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings. The assay is not intended for use in screening blood bank donors. A nonreactive test result does not exclude the possibility of exposure to or infection with hepatitis B. Individuals who have received blood component therapy, e.g., whole blood, plasma, immune globulin administration, during the previous 3 to 6 months may have a false reactive anti-HBs due to passive transfer of anti-HBs. Results from immunosuppressed individuals should be interpreted with caution.
(> 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No false negative findings due to the high-dose hook effect are observed up to an anti-HBs concentration of 115,000 mIU/mL. In rare cases, interference due to extremely high titers of antibodies to analyte- specific antibodies, streptavidin, or ruthenium can occur.
For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings. The assay is not intended for use in screening blood bank donors. A nonreactive test result does not exclude the possibility of exposure to or infection with hepatitis B. Individuals who have received blood component therapy, e.g., whole blood, plasma, immune globulin administration, during the previous 3 to 6 months may have a false reactive anti-HBs due to passive transfer of anti-HBs. Results from immunosuppressed individuals should be interpreted with caution.
Methodology:
Electrochemiluminescence Immunoassay (ECLIA)
CPT Code:
86706